Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00104364 | A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED) | PHASE1 | COMPLETED | 30 | — | — | May 1, 2005 | Jan 1, 2008 | Jan 30, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0731 | DRUG | - |
Inclusion Criteria: * Patients who are at least 18 years of age with recurrent or non-responsive solid tumors, or cancers for whom standard therapy does not exist. Part of the study includes only patients who have taxane-resistant cancers. Exclusion Criteria: * Patients who have had treatment wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |